Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy
(Thomson Reuters ONE) -
Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Praluent(®)
(alirocumab) Study in Patients Undergoing LDL Apheresis Therapy
Paris and Tarrytown, New York - March 23, 2016 - Sanofi and Regeneron
Pharmaceuticals, Inc. today announced positive results from the Phase 3 ODYSSEY
ESCAPE trial evaluating Praluent(®) (alirocumab) Injection in patients with an
inherited form of high cholesterol known as heterozygous familial
hypercholesterolemia (HeFH), whose cholesterol levels required chronic, weekly
or bi-weekly apheresis therapy. The trial met its primary endpoint,
demonstrating that patients who added Praluent to their existing treatment
regimen significantly reduced the frequency of their apheresis therapy by 75
percent, compared to placebo (p<0.0001). Sixty-three percent of patients treated
with Praluent no longer required apheresis, compared to zero percent of placebo
patients. Apheresis is a procedure where bad (LDL) cholesterol is removed from
the blood, in a process similar to kidney dialysis.
"This is the first time a PCSK9 inhibitor has shown in a clinical study that it
reduced the frequency of apheresis therapy, an invasive, difficult to access,
time-consuming and expensive treatment for some of the most difficult-to-treat
patients," said Bill Sasiela, Ph.D, VP, Program Direction, Regeneron. "The
ODYSSEY clinical trial program was designed to understand the effect of Praluent
on many different patient populations with a high degree of unmet need who
required further reduction of their LDL cholesterol."
Apheresis therapy is invasive and burdensome to patients, given that it can take
more than three hours. Treatment may also be inconvenient and cost up to
$100,000 for each patient per year in the U.S. or up to ?60,000 in Germany,
where there are 200 centers and LDL apheresis is more frequently used. In the
U.S. there are only approximately 60 apheresis centers and many patients must
travel significant distances for the procedure.
"Despite statins, a subset of patients with heterozygous familial
hypercholesterolemia are unable to sufficiently reduce their LDL cholesterol,
and require regular apheresis treatment," said Jay Edelberg, MD., Ph.D, Head of
Cardiovascular Development, Sanofi. "The results demonstrate that treatment with
Praluent may help these patients decrease the frequency or even eliminate the
need for apheresis."
The most common adverse events in the trial were fatigue (15 percent Praluent;
10 percent placebo), nasopharyngitis (10 percent Praluent; 10 percent placebo),
diarrhea (10 percent Praluent; 0 percent placebo), myalgia (10 percent Praluent;
5 percent placebo), upper respiratory infection (7 percent Praluent; 19 percent
placebo), headache (7 percent Praluent; 5 percent placebo), arthralgia (7
percent Praluent; 10 percent placebo), and back pain (5 percent Praluent; 10
percent placebo).
Detailed data will be presented at future medical congresses.
About ODYSSEY ESCAPE
The completed Phase 3 placebo-controlled ODYSSEY ESCAPE trial involved 62
patients from 14 treatment centers in the U.S. and Germany. These patients were
receiving regular baseline apheresis therapy at fixed intervals of every week or
every 2 weeks prior to randomization. Patients were randomized to receive
Praluent 150 mg (n=41) subcutaneously every 2 weeks or placebo (n=21), in
addition to their existing treatment regimen. The double-blind treatment period
comprised two intervals: for the first 6 weeks, patients remained on their
established apheresis schedule at baseline, and for the following 12 weeks,
apheresis frequency was adjusted based on the patient's LDL cholesterol response
to treatment. ODYSSEY ESCAPE is part of the overarching Phase 3 ODYSSEY program,
which includes more than 25,000 patients.
About Praluent
In July 2015, the companies announced that Praluent was approved for use in the
U.S. Praluent is a PCSK9 (proprotein convertase subtilisin/kexin type 9)
inhibitor indicated as adjunct to diet and maximally tolerated statin therapy
for the treatment of adults with HeFH or clinical atherosclerotic CVD, who
require additional lowering of LDL cholesterol. The effect of Praluent on CV
morbidity and mortality has not been determined.
In September 2015, the European Commission approved the marketing authorization
for Praluent. In the E.U., Praluent is approved for the treatment of adult
patients with primary hypercholesterolemia (HeFH and non-familial) or mixed
dyslipidemia as an adjunct to diet: a) in combination with a statin, or statin
with other lipid-lowering therapies in patients unable to reach their LDL
cholesterol goals with the maximally-tolerated statin or b) alone or in
combination with other lipid-lowering therapies for patients who are statin
intolerant, or for whom a statin is contraindicated. The effect of Praluent on
CV morbidity and mortality has not yet been determined.
This medicinal product is subject to additional monitoring. This will allow
quick identification of new safety information. Healthcare professionals are
asked to report any suspected adverse reactions.
Important Safety Information for U.S.
Do not use PRALUENT if you are allergic to alirocumab or to any of the
ingredients in PRALUENT.
Before you start using PRALUENT, tell your healthcare provider about all your
medical conditions, including allergies, and if you are pregnant or plan to
become pregnant or if you are breastfeeding or plan to breastfeed.
Tell your healthcare provider or pharmacist about any prescription and over-the-
counter medicines you are taking or plan to take, including natural or herbal
remedies.
PRALUENT can cause serious side effects, including allergic reactions that can
be severe and require treatment in a hospital. Call your healthcare provider or
go to the nearest hospital emergency room right away if you have any symptoms of
an allergic reaction including a severe rash, redness, severe itching, a swollen
face, or trouble breathing.
The most common side effects of PRALUENT include: redness, itching, swelling, or
pain/tenderness at the injection site, symptoms of the common cold, and flu or
flu-like symptoms. Tell your healthcare provider if you have any side effect
that bothers you or that does not go away.
Talk to your doctor about the right way to prepare and give yourself a PRALUENT
injection and follow the "Instructions for Use" that comes with Praluent.
You are encouraged to report negative side effects of prescription drugs to the
FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please click here for the full Prescribing Information
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core strengths in
diabetes solutions, human vaccines, innovative drugs, consumer healthcare,
emerging markets, animal health and Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company
based in Tarrytown, New York that discovers, invents, develops, manufactures,
and commercializes medicines for the treatment of serious medical conditions.
Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a
rare inflammatory condition and has product candidates in development in other
areas of high unmet medical need, including oncology, rheumatoid arthritis,
asthma, atopic dermatitis, pain, and infectious diseases. For additional
information about the company, please visit www.regeneron.com or follow
(at)Regeneron on Twitter.
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. These statements include
projections and estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to future financial
results, events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements are
generally identified by the words "expects", "anticipates", "believes",
"intends", "estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties, many
of which are difficult to predict and generally beyond the control of Sanofi,
that could cause actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other things, the
uncertainties inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as well
as their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence of
guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth opportunities,
trends in exchange rates and prevailing interest rates, the impact of cost
containment initiatives and subsequent changes thereto, the average number of
shares outstanding as well as those discussed or identified in the public
filings with the SEC and the AMF made by Sanofi, including those listed under
"Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements"
in Sanofi's annual report on Form 20-F for the year ended December 31, 2015.
Other than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or statements.
Regeneron Forward-Looking Statements and Use of Digital Media
This news release includes forward-looking statements that involve risks and
uncertainties relating to future events and the future performance of Regeneron
Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or
results may differ materially from these forward-looking statements. Words such
as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate,"
variations of such words, and similar expressions are intended to identify such
forward-looking statements, although not all forward-looking statements contain
these identifying words. These statements concern, and these risks and
uncertainties include, among others, the nature, timing, and possible success
and therapeutic applications of Regeneron's products, product candidates, and
research and clinical programs now underway or planned, including without
limitation Praluent(®) (alirocumab) Injection; unforeseen safety issues and
possible liability resulting from the administration of products (including
without limitation Praluent) and product candidates in patients; serious
complications or side effects in connection with the use of Regeneron's products
and product candidates in clinical trials, such as the ODYSSEY OUTCOMES trial
prospectively assessing the potential of Praluent to demonstrate cardiovascular
benefit; ongoing regulatory obligations and oversight impacting Regeneron's
marketed products (such as Praluent), research and clinical programs, and
business, including those relating to the enrollment, completion, and meeting of
the relevant endpoints of post-approval studies (such as the ODYSSEY OUTCOMES
trial); determinations by regulatory and administrative governmental authorities
which may delay or restrict Regeneron's ability to continue to develop or
commercialize Regeneron's products and product candidates; the likelihood,
timing, and scope of possible regulatory approval and commercial launch of
Regeneron's late-stage product candidates and new indications for marketed
products; competing drugs and product candidates that may be superior to
Regeneron's products and product candidates; uncertainty of market acceptance
and commercial success of Regeneron's products and product candidates and the
impact of studies (whether conducted by Regeneron or others and whether mandated
or voluntary) on the commercial success of Regeneron's products and product
candidates; the ability of Regeneron to manufacture and manage supply chains for
multiple products and product candidates; coverage and reimbursement
determinations by third-party payers, including Medicare and Medicaid;
unanticipated expenses; the costs of developing, producing, and selling
products; the ability of Regeneron to meet any of its sales or other financial
projections or guidance and changes to the assumptions underlying those
projections or guidance; the potential for any license or collaboration
agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare
LLC, to be cancelled or terminated without any further product success; and
risks associated with intellectual property of other parties and pending or
future litigation relating thereto. A more complete description of these and
other material risks can be found in Regeneron's filings with the United States
Securities and Exchange Commission, including its Form 10-K for the year ended
December 31, 2015. Any forward-looking statements are made based on management's
current beliefs and judgment, and the reader is cautioned not to rely on any
forward-looking statements made by Regeneron. Regeneron does not undertake any
obligation to update publicly any forward-looking statement, including without
limitation any financial projection or guidance, whether as a result of new
information, future events, or otherwise.
Regeneron uses its media and investor relations website and social media outlets
to publish important information about the Company, including information that
may be deemed material to investors. Financial and other information about
Regeneron is routinely posted and is accessible on Regeneron's media and
investor relations website (http://newsroom.regeneron.com) and its Twitter feed
(http://twitter.com/regeneron).
Contacts Sanofi:
Media Relations Investor Relations
Jack Cox Sébastien Martel
Tel: +33 (0)1 53 77 46 46 Tel: +33 (0)1 53 77 45 45
mr(at)sanofi.com ir(at)sanofi.com
Contacts Regeneron:
Media Relations Investor Relations
Arleen Goldenberg Manisha Narasimhan, Ph.D.
Tel: +1 (914) 847-3456 Tel: +1 (914) 847-5126
Mobile: +1 (914) 260-8788 manisha.narasimhan(at)regeneron.com
arleen.goldenberg(at)regeneron.com
Press Release (PDF):
http://hugin.info/152918/R/1996750/735872.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Sanofi via GlobeNewswire
[HUG#1996750]
Unternehmensinformation / Kurzprofil:
Datum: 23.03.2016 - 07:01 Uhr
Sprache: Deutsch
News-ID 459316
Anzahl Zeichen: 17884
contact information:
Town:
PARIS
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 326 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy"
steht unter der journalistisch-redaktionellen Verantwortung von
Sanofi (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
